Needham & Company Maintains a 'Hold' on Omeros Corp. (OMER); 2012 Preview
Tweet
Share
E-mailGet Alerts OMER Hot Sheet
Price: $17.12 -0.41%
Rating Summary:
8 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
8 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Omeros Corp. (NASDAQ: OMER).
Needham analyst says, "Omeros initiated Phase 3 trials of OMS302 (Ketorolac/ Phenylephrine) in eye surgery and OMS-103HP (Ketoprofen, Amitriptyline, and Oxymetazoline) in meniscectomy surgery in 2011. Results from the former are expected in 1Q12 and from the latter around mid-2012. Both trials continue to enroll patients. Encouraging indications of activity were seen in prior corresponding Phase 2 trials. However, we are cautious around the company’s pharmacosurgery programs given the failure of OMS103HP in an ACL surgery trial in 2011."
"The company has reported substantial progress in its screening effort against orphan GPCRs, having identified leads against at least 16 targets. Management plans to seek collaborators prior to advancing these programs through development...Omeros ended 3Q11 with $32.9M in cash. We believe this is sufficient through 2012."
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $4.02 yesterday.
Needham analyst says, "Omeros initiated Phase 3 trials of OMS302 (Ketorolac/ Phenylephrine) in eye surgery and OMS-103HP (Ketoprofen, Amitriptyline, and Oxymetazoline) in meniscectomy surgery in 2011. Results from the former are expected in 1Q12 and from the latter around mid-2012. Both trials continue to enroll patients. Encouraging indications of activity were seen in prior corresponding Phase 2 trials. However, we are cautious around the company’s pharmacosurgery programs given the failure of OMS103HP in an ACL surgery trial in 2011."
"The company has reported substantial progress in its screening effort against orphan GPCRs, having identified leads against at least 16 targets. Management plans to seek collaborators prior to advancing these programs through development...Omeros ended 3Q11 with $32.9M in cash. We believe this is sufficient through 2012."
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $4.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
